Wave Life Sciences aligns with FDA. Wave Life Sciences stock gains 2.11 percent

Published on 10/06/2026 at 15:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA supports a two-year trial with a one-year interim review. Wave Life Sciences stock costs EUR 3.39 on October 6, 2026 after EUR 3.32.

WVE, US94352A1043, Illustration mit AI erstellt.

Wave Life Sciences (ISIN US94352A1043) was trading at EUR 3.39 at Lang & Schwarz on October 6, 2026 at 2:59 p.m. CEST, up 2.11 percent from the EUR 3.32 prior close. On October 1, 2026, GlobeNewswire reported that Wave aligned with the FDA on a single two-year registrational trial for WVE-006, with a one-year interim analysis that could support potential accelerated approval.

FDA path uses one trial

The planned study is designed to support potential full approval without a separate confirmatory trial, according to the company release dated October 1, 2026. The FDA also supported Wave's current LC-MS assay for measuring normal M-AAT and mutant Z-AAT proteins in the WVE-006 program.

Wave expects to share data from the 600 mg monthly multidose cohort of the RestorAATion-2 trial in the fourth quarter of 2026. The program is testing WVE-006 in people with alpha-1 antitrypsin deficiency and the homozygous Pi*ZZ mutation.

Analysts weigh the Q2 shortfall

Investing.com reported on October 2, 2026 that H.C. Wainwright maintained a Buy rating and a USD 13.00 price target. The report also said Wave posted an adjusted loss of USD 0.34 per share in the second quarter of 2026, compared with a USD 0.30 consensus loss.

Revenue reached USD 2.3 million in the second quarter of 2026 against USD 7.65 million expected, according to the same October 2, 2026 report. That gap makes the clinical timetable more important because the near-term investment case depends on progress toward WVE-006 data and additional pipeline milestones.

Nasdaq range remains wide

On Nasdaq, WVE was trading at USD 3.75 at 4:00 p.m. ET on October 5, 2026. The 52-week range was USD 3.56 to USD 21.73, while market capitalization stood at USD 738.9 million on the same quote date.

EUR 3.39 in trading

At Lang & Schwarz, Wave Life Sciences stock was trading at EUR 3.39 on October 6, 2026 at 2:59 p.m. CEST, plus 2.11 percent versus the EUR 3.32 prior close. The euro quote is the relevant German-market reference, while the Nasdaq figures provide separate U.S. market context.